AstraZeneca to Strengthen Presence in California with New South San Francisco Location
Move will create scientific site for more than 350 local employees
GAITHERSBURG, MD., September 27, 2016 – AstraZeneca, together with its global biologics research and development arm MedImmune, today revealed plans to bring together five of its Bay Area sites into one location in South San Francisco. The new site will be located in the Cove at Oyster Point with cutting-edge lab space and offices. More than 350 employees in existing AstraZeneca, Acerta Pharma, MedImmune, and Pearl R&D facilities will move to the new location beginning in Q4 2017.
The move demonstrates AstraZeneca’s continued commitment and investment in a strong and visible presence in California, and the new location will serve as a valuable source of talent and partnership opportunities, as well as provide convenient access to strategic suppliers. Additionally, it will serve to strengthen the company’s presence in the Bay Area biopharma landscape, which remains a leading global bioscience cluster. The company also anticipates some cost benefits associated with the move, such as better space utilization, improved energy efficiency, and other operating benefits.
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “Our new South San Francisco location—where biotech and Silicon Valley intersect—brings all of our California employees to one site and provides opportunities to access exciting science both inside and outside our walls. We are proud to create an open, welcoming, and vibrant center that will inspire our teams and partners to continue to push the boundaries of scientific innovation.”